Month: May 2026

Posted on

Hybrid fluoroscopy–neuronavigation technique for percutaneous balloon compression in trigeminal neuralgia

Acta Neurochirurgica (2026) 168:110

This article presents a hybrid fluoroscopy–electromagnetic neuronavigation technique for percutaneous balloon compression in trigeminal neuralgia, detailing preoperative CT trajectory planning, intraoperative dual guidance, and practical steps to optimize foramen ovale cannulation. Emphasis is placed on safety measures, anesthesia considerations, and procedural specifics such as entry point, stylet use, and balloon inflation parameters.

The manuscript discusses candidate selection, advantages for elderly or comorbid patients, limitations including equipment needs and limited evidence, and practical tips to minimize complications. Key points summarize indications, procedural timing, anatomical landmarks, and the hybrid approach’s potential to shorten the learning curve for junior surgeons.

Purpose: Hybrid fluoroscopy + electromagnetic neuronavigation improves accuracy and safety of foramen ovale cannulation for percutaneous balloon compression in trigeminal neuralgia, reducing multiple passes in anatomically variable cases

Planning: Preoperative thin-slice CT is used to design an individualized needle trajectory to the foramen ovale, sometimes modifying the classical Hartel entry point to avoid bony collision

Anesthesia: Performed under general anesthesia because trigeminal ganglion manipulation can trigger a vagal reflex causing severe bradycardia/asystole; atropine readiness is required

Setup & entry: Patient supine with slight head extension; entry point is typically ~2.5 cm lateral to the oral commissure, with neuronavigation confirming the skin site/trajectory and C-arm fluoroscopy providing real-time position checks

Needle guidance: Needle advanced under fluoroscopy toward the petrous ridge–clivus junction (lateral view alignment), then an electromagnetic sensor/stylet is inserted to confirm and fine-tune alignment with the preplanned path before FO passage

Balloon step: After cannulation, a 4F Fogarty balloon is inflated with ~0.75 ml iopamidol to achieve the characteristic pear-shaped configuration under fluoroscopy

Compression time: Balloon compression is maintained for ~1–3 minutes to balance pain relief with risks such as hypoesthesia and masticatory weakness; limit to a maximum of 3 minutes

Clinical role & limits: Useful for medication-refractory TN, especially elderly/comorbid patients or when MRI shows no neurovascular conflict; limitations include added cost/skill needs and low evidence base (lack of randomized trials)

Posted on

Guidelines for the Treatment of Adults With WHO Grade II Diffuse Glioma: Update

Neurosurgery 98:984–991, 2026

These updated CNS evidence-based guidelines consolidate current literature on the management of WHO grade II diffuse gliomas, covering imaging, surgical strategies, neuropathology, radiotherapy, chemotherapy, and recurrence. They summarize evidence levels, provide topic-specific recommendations, and identify areas needing higher-quality research to inform clinical decisions.

The document details unchanged, updated, and new recommendations—ranging from MRI protocols and intraoperative mapping to molecular testing and adjuvant therapy—while describing methodology, conflict-of-interest procedures, and plans for periodic revision to ensure clinical relevance.

Scope: Updated evidence-based recommendations for adult WHO grade II diffuse glioma across imaging, surgery, neuropathology/molecular markers, radiotherapy, chemotherapy, and recurrence management.

Methods: Systematic search of MEDLINE/Embase/Cochrane covering Jan 1, 2013–Jan 31, 2020, with recommendations based on evidence rather than consensus.

Imaging (minimum MRI): Minimum evaluation includes T2-weighted and pre- and post-gadolinium T1-weighted MRI; serial imaging is used to detect new enhancement or significant growth suggesting higher-grade transformation.

Imaging (advanced/PET): Diffusion plus perfusion techniques (e.g., DSC/DCE/ASL) are suggested when standard MRI cannot distinguish grade II from higher-grade gliomas; amino-acid PET (FET or FDOPA) may be added when not evident on MRI to help with grading, prognosis (FET), or progression detection (FDOPA).

Surgery: When safe/feasible, resection (gross total or subtotal) is recommended over biopsy alone to reduce progression; extent of resection should be maximized when safely possible (including for IDH-mutant and IDH–wild-type tumors).

Pathology/molecular testing: Diagnosis relies on histopathology from representative tissue; IDH mutation testing is recommended for classification/prognosis, and 1p/19q loss-of-heterozygosity testing is recommended in oligodendroglial cases for prognosis/treatment planning.

Adjuvant therapy (high-risk): For high-risk grade II diffuse glioma (age >40 or <40 without gross total resection), adding chemotherapy to radiotherapy is recommended to improve overall survival (including procarbazine/PCV-based approaches) and is also recommended without decline in neurocognitive function.

Recurrence: At suspected recurrence, advanced imaging (MRS/perfusion/diffusion/PET) is suggested; temozolomide is suggested (often initial choice) and procarbazine may help (strongest evidence in oligodendroglioma); radiation is suggested if not previously given and reirradiation may be considered.

Posted on

How much do patients benefit in quality of life after surgery for cervical spondylotic myelopathy? A Spine CORe™ analysis of QOD data

Neurosurg Focus 60(5):E2, 2026

This multicenter Quality Outcomes Database analysis evaluates long-term quality of life after surgery for cervical spondylotic myelopathy (CSM), using EQ-5D scores at baseline and 3, 12, 24, and 60 months. The study reports significant, durable postoperative EQ-5D improvements and a mean gain of 0.72 QALYs at five years across a large surgical cohort.

The analysis identifies predictors of clinically meaningful improvement: worse baseline EQ-5D increased odds of improvement, while greater baseline neck pain severity and undergoing anterior cervical corpectomy and fusion (ACCF) decreased those odds. Complication and mortality rates were low, supporting sustained quality-of-life benefits of CSM surgery.

Objective Assess long-term postoperative quality-of-life benefit after surgery for cervical spondylotic myelopathy (CSM) and identify factors linked to meaningful improvement.

Methods Post hoc analysis of a prospectively collected, 14-site QOD CSM cohort using EQ-5D at baseline and 3, 12, 24, and 60 months; MCID for EQ-5D defined as 0.11; multivariable logistic regression used to find predictors of 60-month MCID achievement.

Cohort At 60 months, follow-up status was available for 895/1085 patients (82.4%); 788 patients had 60-month EQ-5D data for the main EQ-5D analysis.

Quality-of-life gains Mean EQ-5D improved from 0.58 ± 0.22 preop to 0.76 ± 0.22 at 60 months (p < 0.001), with improvements evident by 3 months and sustained through 5 years.

Clinically meaningful benefit 58.7% of patients achieved the EQ-5D MCID at 60 months.

Negative predictors Greater baseline neck pain severity and undergoing ACCF (anterior cervical corpectomy and fusion) were independently associated with lower odds of achieving the 60-month EQ-5D MCID.

Positive predictor Worse baseline quality of life (lower baseline EQ-5D) was associated with increased odds of achieving long-term (60-month) MCID improvement.

QALYs Mean gain after surgery was 0.72 ± 1.11 QALYs over 60 months (calculated via area-under-the-curve with baseline-projected QALYs subtracted).

Posted on

Transforming Neurosurgery With Spatial Computing: Enhancing Intraoperative Visualization and Precision Through Augmented Reality

Operative Neurosurgery 30:760–764, 2026

This technical note reports three neurosurgical cases using the Medivis surgical augmented reality platform with the Microsoft HoloLens 2 to overlay real-time 3D imaging, exoscopic, and endoscopic outputs intraoperatively. The workflow, registration method, hardware and software integration, and case-specific operative details are described, with all patients recovering without complications.

The report evaluates benefits and limitations of wearable XR in the operating room, highlighting improved visualization, surgical precision, and ergonomics, while addressing challenges such as registration accuracy, latency, cognitive overload, and avenues for future hardware and software improvements.

Goal Integrate wearable XR/AR and spatial computing into neurosurgical operating rooms to enhance intraoperative visualization, precision, and ergonomics.

System setup Three neurosurgical cases used the Medivis SurgicalAR platform paired with a Microsoft HoloLens 2 worn by the primary surgeon, enabling overlay of 3D volumes and intraoperative video in the surgeon’s field of view.

Imaging workflow Preoperative CT/MRI (including tractography/connectomic imaging when available) were uploaded from PACS, processed quickly (windowing/coloring/cropping/brightening), and stored for OR use, then linked to the HoloLens.

Registration approach Intraoperative holographic point-matching registration matched physical landmarks on the patient to virtual fiducials via an optical localizer recognized by HoloLens 2, with an FDA-approved navigation system also used in all cases for confirmation.

Video integration Exoscopic/endoscopic outputs were captured and streamed to the AR computer and transmitted to the HoloLens for real-time manipulation and interaction by the surgeon.

Observed benefits Combined overlays improved visualization and supported ergonomic operating posture, optimized sight lines, and reduced OR footprint while maintaining standard team visualization via the exoscope monitor.

Case outcomes All three patients recovered well postoperatively without complications; no critical intraoperative issues from latency/dropped frames prevented procedure completion.

Limitations & next steps Key challenges include potential cognitive overload/inattentional blindness, hologram registration accuracy, and technical issues like latency/dropped frames; future work targets improved/universal registration and broader overlayable data streams (e.g., conferencing, checklists).

Posted on

Incidence and risk factors of adjacent segment degeneration in lumbosacral or lumbo-iliac fusion with L2 as the uppermost instrumented vertebra

J Neurosurg Spine 44:693–703, 2026

This clinical retrospective study evaluates the incidence and risk factors for symptomatic adjacent segment degeneration (ASD) after instrumented fusion from L2 to the sacrum or ilium in 89 adults treated for diffuse lumbar degeneration or mild–moderate deformity. Over a mean 38.6-month follow-up, 40% developed symptomatic L1–2 ASD and 23.6% required revision, with Kaplan-Meier ASD-free rates of 79% at 1 year and 59% at 3 years.

Multivariate analysis identified L2–3 decompression, preexisting advanced L1–2 disc degeneration, greater postoperative PI–LL mismatch, and higher lordosis distribution index as independent ASD risk factors; distal failures (13.5%) were linked to male sex, younger age, and absence of iliac screws. The authors recommend careful selection of L2 as UIV, balanced lordosis restoration, and consideration of pelvic fixation to mitigate proximal and distal complications.

Aim Quantify incidence of symptomatic adjacent segment degeneration (ASD) after instrumented fusion from L2 (UIV) to sacrum or ilium and identify associated risk factors.

Design/definition Retrospective review (Jan 2016–Dec 2023) of adults undergoing first-time L2–S1/ilium fusion; symptomatic ASD defined by new/worsening pain or neurologic symptoms with L1–2 degenerative/junctional changes (e.g., disc degeneration/stenosis progression, listhesis, junctional kyphosis, fracture, or UIV fixation failure).

Cohort 89 patients (mean age 68.5 years) with mean follow-up 38.6 months.

ASD incidence 36/89 (40%) developed symptomatic ASD at L1–2; mean time to ASD 21 months; 21/89 (23.6%) required reoperation.

ASD-free survival Kaplan-Meier ASD-free rates: 79% at 1 year, 68% at 2 years, 59% at 3 years (mean ASD-free period 52.8 months).

ASD risk factors Higher ASD risk associated with simultaneous decompression at L2–3, preexisting advanced L1–2 disc degeneration, greater postoperative PI-LL mismatch, and higher lordosis distribution index (LDI).

Distal failure incidence 12/89 (13.5%) developed distal failure (including 9 L5–S1 pseudarthroses, 2 sacral fractures, 1 rod fracture); mean time 19 months.

Distal failure risk factors Male sex, younger age, and lack of iliac screws increased risk of distal failure.

Posted on

Defining the target for hemifacial spasm –regarding microvascular decompression

Acta Neurochirurgica (2026) 168:103

This paper argues that the physiologic target for microvascular decompression (MVD) in hemifacial spasm (HFS) is the full extent of the centrally myelinated facial root exit zone (fREZ), from the pontomedullary sulcus (root exit point) to the transitional zone, rather than the shorter REZ segment often emphasized. The authors critique recent anatomical definitions and highlight histological and intraoperative evidence supporting a longer susceptible CMP.

The manuscript details four fREZ segments (RExP, attached segment, root detachment point, TZ), presents frequency data of culprit compressions concentrated on the attached segment, and stresses diagnostic-imaging and surgical implications. Adopting the expanded fREZ map and subfloccular approach is presented as essential to reduce failed MVDs for HFS.

Target definition problem: Equating the cranial nerve REZ with just the short segment between the brainstem surface and the TZ does not accurately represent the physiologically vulnerable central myelin portion (CMP) of the facial nerve in hemifacial spasm surgery.

Facial CMP length: The facial nerve’s exposed centrally myelinated fibers extend proximally along the pontine surface and are considerably longer (about ~1 cm) than the commonly measured brainstem-to-TZ segment.

Expanded fREZ anatomy: A practical surgical definition divides the facial root exit zone (fREZ) into four parts—RExP (root exit point at the pontomedullary sulcus), AS (attached segment adherent to the pons), RDP (root detachment point), and distal TZ (2–3 mm beyond RDP).

Physiologic susceptibility zone: The vulnerable target for MVD in HFS is the entire exposed centrally myelinated facial segment from the pontomedullary sulcus (RExP) to the TZ, not only the short “REZ” segment near the brainstem edge.

Compression distribution: Culprit neurovascular compression in HFS occurs most often along the AS (~80%), less at RExP (~10%) and RDP–TZ (~10%), and only rarely on the distal cisternal portion (typically with severe distortion).

Imaging implication: Diagnostic imaging interpretation for HFS should assess the most proximal fREZ (RExP and AS) rather than focusing only distal to the RDP.

Surgical failure mechanism: Failed MVD can result when decompression is directed at more distal facial nerve portions, missing persistent compression at the true proximal anatomical target.

Approach to access target: A subfloccular approach helps reach the proximal fREZ by tracking glossopharyngeal fibers to the brainstem, supporting effective decompression of the susceptible proximal segment.

Posted on

Predictors of shunt responsiveness and outcomes in idiopathic normal pressure hydrocephalus: a retrospective cohort study

Acta Neurochirurgica (2026) 168:80

This retrospective cohort study from Tel-Aviv Medical Center evaluates predictors of clinical improvement after shunt placement in patients with idiopathic normal pressure hydrocephalus (iNPH) assessed between 2020–2022. The authors analyze clinical presentation, standardized gait testing, MRI features (including DESH), CSF biomarkers (notably total tau and protein), and PET findings to determine associations with lumbar puncture (LP) responsiveness and one-year post-shunt outcomes.

Key findings show 37% LP responsiveness among 167 patients, 38 underwent shunting, and 55% of shunted patients had favorable one‑year outcomes. Lower CSF total tau and presence of a DESH imaging pattern correlated with LP response and improved one‑year outcomes, while greater immediate post‑LP gait improvement predicted sustained benefit; vascular comorbidities and standard MRI metrics were less predictive.

Objective Identify clinical, imaging, and CSF biomarkers linked to favorable outcomes after shunt placement in suspected idiopathic normal pressure hydrocephalus (iNPH).

Cohort & pathway 183 patients were evaluated (2020–2022); 167 underwent high-volume lumbar puncture (≥30 mL removed); LP responders were referred for shunting and followed for 1 year.

LP responsiveness rate 62/167 (37%) improved after CSF drainage and were referred for shunt surgery; 38/62 (61%) ultimately underwent shunt placement.

Clinical pattern Gait disturbance was the most common presenting symptom (68%) and was more frequent in LP responders, while cognitive symptoms were more common among non-responders (29.5% vs 10%).

CSF biomarkers (LP response) LP responders had lower CSF total tau (t-tau) and protein than non-responders.

Imaging marker (LP response) The DESH pattern was more common in LP responders (73% vs 46%).

Shunt outcomes (1 year) 21/38 (55%) shunted patients had a favorable outcome at one year; favorable outcome was associated with more frequent DESH and lower t-tau (trend).

Overall takeaway Combining post-LP clinical response with DESH imaging and CSF t-tau may help refine selection for shunting and predict better outcomes.

Posted on

Clinical Outcomes of Subarachnoid Hemorrhage in Patients With Nicotine Dependence

Neurosurgery 98:1095–1102, 2026

This retrospective, population-based study analyzes clinical outcomes after nontraumatic subarachnoid hemorrhage (SAH) among 43,315 patients with documented nicotine dependence versus patients without substance use disorders. Using the TriNetX network with propensity score matching, primary endpoints included mortality, vasospasm, hydrocephalus, and delayed cerebral ischemia (DCI), with nicotine dependence associated with significantly higher hazards for all outcomes.

The manuscript details methods, matching variables, statistical analyses, mechanistic discussion of nicotine’s vascular effects, and limitations inherent to large electronic health record databases. Conclusions emphasize that nicotine dependence predicts worse SAH outcomes and support prioritizing smoking cessation counseling as part of long-term patient management.

Study focus: Clinical outcomes after nontraumatic subarachnoid hemorrhage (SAH) in adults with nicotine dependence versus those with no substance use disorder diagnoses.

Data source & cohort: TriNetX electronic medical record network analysis of adults (≥18) with ICD-10 I60 (nontraumatic SAH) from 2004–2024; 43,315 had nicotine dependence (F17) out of ~210k+ SAH patients.

Methods: Used 1:1 propensity score matching to balance demographics, comorbidities, lab/substance testing, and SAH severity (NIS-SAH Severity Score elements), then applied Cox proportional hazards and Kaplan–Meier survival analyses.

Mortality risk: Nicotine dependence associated with higher post-SAH mortality hazard (HR ≈ 1.24–1.25, statistically significant).

Vasospasm risk: Nicotine dependence associated with higher hazard of vasospasm (HR ≈ 1.47–1.49, statistically significant).

DCI risk: Nicotine dependence associated with higher hazard of delayed cerebral ischemia (DCI) (HR reported ≈ 1.30–1.35, statistically significant).

Hydrocephalus risk: Nicotine dependence associated with higher hazard of newly diagnosed hydrocephalus (HR ≈ 1.27, statistically significant).

Clinical implication: Elevated risks linked to nicotine dependence underscore the importance of smoking cessation counseling for long-term management after SAH.

Posted on

The utility of partial sensory rhizotomy and adjunct procedures in the surgical management of trigeminal neuralgia secondary to multiple sclerosis

J Neurosurg 144:1145–1153, 2026

This clinical study evaluates long-term outcomes of partial sensory rhizotomy (PSR) for trigeminal neuralgia (TN) secondary to multiple sclerosis (MS), comparing PSR alone, redo PSR, and PSR combined with microvascular decompression (MVD) or internal neurolysis (IN). Retrospective analysis of 37 procedures in 30 patients shows high immediate pain relief (89.2%), mean recurrence at 1.64 years, and variable durability across groups.

At final follow-up, combination therapy (PSR+MVD or PSR+IN) trended toward superior sustained pain freedom without increased complications, while first PSR commonly required additional interventions. The authors conclude PSR is an effective salvage option and suggest adjunctive MVD or IN may improve long-term outcomes, recommending prospective validation.

Objective Evaluate long-term outcomes of partial sensory rhizotomy (PSR) alone versus PSR combined with microvascular decompression (MVD) or internal neurolysis (IN) for trigeminal neuralgia secondary to multiple sclerosis.

Methods Retrospective review of PSR cases (2012–2023) grouped as first PSR, redo PSR, PSR+MVD, and PSR+IN; assessed pain outcomes, recurrence, and complications.

Cohort 30 patients underwent 37 procedures; 89.2% of procedures followed at least one prior ipsilateral TN procedure.

Immediate outcomes 89.2% achieved immediate postoperative pain relief (pain free with or without medication), with no significant differences between procedure groups.

Durability Pain recurred on average at 1.64 ± 1.71 years after the procedure, with no significant differences among groups.

Final follow-up pain freedom At mean 3.14 ± 2.58 years follow-up, 75% of PSR+MVD and 100% of PSR+IN cases were pain free; 52.3% of first PSR cases required additional procedures.

Complications Overall complication rate was 29.7% with no significant differences between groups; ipsilateral facial numbness was common (59.5%) and treated as an expected outcome rather than a complication.

Conclusion PSR functions effectively as a salvage option for MS-related TN, and adding MVD or IN may improve long-term pain relief without increasing complication rates.

Posted on

Disruptive technologies in spine surgery: current trends, outcomes, and ethical implications

J Neurosurg Spine 44:756–768, 2026

Disruptive technologies in spine surgery—AR/VR, robotics, neuronavigation, endoscopy, and patient-specific implants—are examined for their roles in enhancing precision, training, and patient outcomes. The review summarizes evidence for preoperative simulation, AR-assisted planning, and 3D segmentation, highlighting improvements in accuracy, reduced fluoroscopy, and trainee confidence.

Intraoperative advances such as robot-assisted techniques, computer-assisted navigation, and endoscopic approaches offer minimally invasive alternatives with favorable recovery profiles but face challenges of cost, learning curves, and equitable access. The authors emphasize ethical considerations, need for standardized outcomes, and strategies to expand accessibility and training.

Scope Disruptive spine-surgery technologies emphasized include AR/VR (XR), advanced navigation, robotics, patient-specific implants/3D printing, and endoscopic spine surgery.

XR definitions VR provides a fully immersive digital environment, AR overlays digital content onto the real world, and MR blends both; all fall under XR.

Training impact VR simulation in spine training improved trainee comfort and autonomy and reduced fluoroscopy use in lateral lumbar interbody fusion simulations; VR-trained learners also made fewer pedicle-screw placement errors than traditional instruction.

Preop planning VR-based planning can reduce fluoroscopy/localization time and improve puncture accuracy in endoscopic lumbar discectomy; segmented 3D models support rehearsal, trajectory planning, and risk assessment around critical structures.

AR navigation outcomes Wearable AR navigation (e.g., FDA-cleared xvision) has shown high pedicle-screw placement accuracy (reported ~96.7% thoracic and ~99.1% lumbosacral) and may reduce operative time and radiation exposure.

Patient-specific surgery Segmentation + 3D printing/predictive modeling enable personalized approaches and implants (e.g., patient-specific rods, templates, custom cages), with early reports of high accuracy for template-guided instrumentation and promising feasibility for custom interbody devices.

Endoscopic techniques ESS supports minimally invasive treatment across multiple pathologies and can match conventional outcomes for lumbar disc herniation while improving recovery (e.g., shorter stays/earlier return to work), but broader adoption is constrained by learning curve and reimbursement challenges.

Implementation ethics/costs High acquisition/maintenance costs and limited reimbursement risk widening access disparities; recommended mitigations include subsidized training, shared equipment models, and reimbursement policies to support equitable implementation alongside standardized outcomes and training.

Posted on

Chronic Oculomotor Nerve Palsy Presentation From Posterior Communicating Artery Aneurysm

Operative Neurosurgery 30:703–710, 2026

This case series analyzes 17 patients with subacute to chronic oculomotor nerve palsy (ONP) caused by posterior communicating artery (PCoA) aneurysms treated between 1991 and 2024. Demographics, aneurysm characteristics, treatment modalities (clipping vs endovascular), and follow-up outcomes are reported, highlighting that only a minority presented with rupture.

The report finds that complete ONP recovery occurred exclusively in patients treated within five weeks of symptom onset, supporting early definitive management to maximize functional nerve recovery despite chronic ONP not reliably predicting imminent aneurysm rupture.

Clinical question: The natural history of chronic oculomotor nerve palsy (ONP) from posterior communicating artery (PCoA) aneurysm is unclear, especially regarding rupture risk and likelihood of nerve recovery when symptoms persist beyond 1 week.

Cohort & design: Case series from a prospectively accrued institutional database (1991–2024) including patients with ≥1 week ONP attributed to PCoA aneurysm; patients with <1 week onset, inadequate follow-up, or other causes of ONP were excluded.

Patient profile: 17 patients; predominantly female (94.1%), median age 56; ONP duration ranged 1 week to 10 years; 29.4% presented with aneurysm rupture.

Treatment approaches: Most were treated with microsurgical clipping (64.7%) or endovascular therapy (29.4%); one patient was managed conservatively due to comorbidities/limited life expectancy.

ONP recovery outcomes: Complete ONP recovery occurred in 23.5% (4/17); all complete recoveries were in patients with symptom duration <5 weeks.

Timing signal: Subacute ONP (<5 weeks) was associated with better recovery (including complete recovery), while chronic ONP (≥5 weeks) had no complete recoveries in this cohort.

Rupture implication: Chronic ONP appeared not to indicate imminent rupture, with only about one-third presenting ruptured and an example of 10 years of stable ONP preceding rupture in the longest-duration case.

Management takeaway: Even if chronic ONP may not predict near-term rupture, early definitive aneurysm treatment is still recommended to maximize the chance of functional ONP recovery.

Posted on

Quality-of-Life Outcomes in Adults and Children With Chiari 1 Malformation and in Those Managed Without Surgery

Neurosurgery 98:1113–1128, 2026

This multicenter prospective study evaluates health-related quality of life (HRQoL) in adults and children with Chiari 1 malformation (CM1) who were managed without surgery, comparing baseline and 12-month patient-reported outcomes. Using SF-36 for adults and PedsQL for children, the UK Chiari 1 Study found baseline HRQoL was lower than normative data but showed overall stability at 12 months for nonsurgical patients.

The study reports symptom prevalence, imaging characteristics, and management decisions across 192 participants, identifying limb and back pain, poor balance, syringomyelia, and psychiatric comorbidity as factors associated with worse HRQoL. Results support cautious nonoperative management for many patients and call for larger, longer-term comparative studies between surgical and nonsurgical care.

Study focus: Prospective, multicenter UK observational cohort measuring health-related quality of life in adults (SF-36) and children (PedsQL) with Chiari 1 malformation (CM1) managed without surgery, from first neurosurgical clinic review to 12 months later.

Baseline HRQoL: Quality-of-life scores at baseline were significantly lower than normative control data across every domain in both adults and children.

Cohort size/follow-up: 192 patients had baseline data; 113 nonsurgical patients had 12-month follow-up data (146 female; 148 adults in baseline cohort).

12-month change (overall): No decreases in quality-of-life subscores over 12 months in adults or children managed without surgery.

Adult improvements: In adults managed without surgery, social functioning and bodily pain SF-36 subscores improved at 12 months (social functioning: t = −4.0, P < .001; bodily pain: t = −2.9, P = .03).

Symptoms at presentation: Headache was most prevalent (79.2% overall), including occipital headache (65.1%) and Valsalva-induced headache (54.2); headache and Valsalva headache were more common in adults than children.

Imaging findings: Median maximum cerebellar tonsillar descent was 10 mm (IQR 7–13); syringomyelia was present in 25.2% of those with spine MRI available for review.

Clinical implications/next steps: HRQoL stability over 12 months supports reassurance/counseling for selected mildly symptomatic or borderline cases, while emphasizing need for robust surgical vs nonsurgical comparisons and longer-term study.

Posted on

Health-Related Quality-of-Life Outcomes in Surgical Patients With Sacral Tarlov Cysts: A 2-Year Prospective Study

Neurosurgery 98:1156–1165, 2026

This prospective longitudinal study reports clinical and patient-reported health-related quality-of-life outcomes for 417 adults who underwent surgical treatment for symptomatic sacral Tarlov cysts, with standardized assessments at baseline and 3, 6, 12, and 24 months. Using the disease-specific TCQoL alongside SF-36, ODI, and VAS, the study demonstrates statistically significant and clinically meaningful improvements across most domains, low complication rates, and no radiographic cyst recurrence at early follow-up.

The authors detail a microsurgical posterior sacral laminectomy technique with cyst decompression, dural sleeve wrapping, and laminar reconstruction, and report sustained benefits through 2 years, including increased tolerated sitting time and reduced opioid use. Limitations include attrition and missing data addressed by imputation, and the paper advocates broader adoption of the TCQoL for standardized Tarlov cyst research.

Study aim Assess whether surgical treatment for symptomatic sacral Tarlov cysts improves validated general and disease-specific health-related quality of life (HRQoL) through 2 years post-op, and whether outcomes change from year 1 to year 2.

Design & cohort Retrospective analysis of prospectively collected longitudinal outcomes for adults undergoing first-time surgery for ≥1 sacral Tarlov cyst (2008–2023), performed by a single neurosurgeon; 417 patients (mean age 52.5, 91.1% female).

Outcome measures Primary outcome was the TCQoL (11-item disease-specific scale); secondary measures included VAS pain (rest/activity), ODI, and SF-36, collected pre-op and at 3, 6, 12, and 24 months.

Surgical technique Posterior sacral laminectomy with microsurgical dissection, cyst drainage to normalize root caliber, wrapping the cystic nerve root with bovine pericardium dural substitute sleeve to limit refilling, and covering the laminar window with a resorbable plate/screws.

2-year improvements (key metrics) Significant improvements from pre-op to 2 years in TCQoL (3.2→2.1), VAS pain at rest (4.5→2.3) and activity (5.7→3.1), and ODI (45.5→31.6) (all P<.001).

SF-36 domains Improvement occurred in 7/8 SF-36 scales (Physical Functioning, Physical Limitations, Bodily Pain, Vitality, Social Functioning, Emotional Limitations, Mental Health), while General Health was not statistically significant in the imputed analysis.

Year 1 to year 2 change Most subscales did not change significantly from 1 to 2 years; significant further gains were seen in physical functioning and social functioning (P=.040 and P=.016, respectively).

Sitting tolerance Median tolerated sitting time increased from 15 minutes pre-op to 45 minutes at 2 years post-op.

Posted on

The role of surveillance MRI scans in patients with sporadic cerebral cavernous malformations

J Neurosurg 144:1017–1023, 2026

This clinical study assesses the diagnostic value of routine versus symptom-driven MRI follow-up in patients with sporadic cerebral cavernous malformations (CCMs), analyzing radiographic changes at the first postdiagnosis scan in a prospective single-center cohort. Results show that new or worsening focal neurological deficit (FND) strongly predicts symptomatic hemorrhage, while routine surveillance rarely detects acute hemorrhage.

Imaging progression—including lesion growth, Zabramski classification changes, T1 hyperintensity, and edema—occurred across indications but had limited impact on management when patients were asymptomatic. The authors recommend symptom-driven MRI, reserving routine surveillance for select cases and early posthemorrhage confirmation.

Objective Evaluate whether routine surveillance MRI vs symptom-driven MRI better detects hemorrhage in patients with sporadic, brain-only cerebral cavernous malformations (CCMs), and what radiographic changes appear at first follow-up.

Cohort/Design Prospective single-center registry analysis of 236 sporadic brain-only CCM patients who had ≥1 follow-up MRI after diagnosis; MRI indications categorized as routine vs symptom-driven (e.g., new/worsening focal neurological deficit [FND], headache, seizure).

Hemorrhage yield Radiographic hemorrhage at first follow-up occurred in 19.1% (13/68) of symptom-driven MRIs vs 1.2% (2/168) of routine/non–CCM-related surveillance MRIs.

Routine progression In routine/non–CCM-related surveillance (n=168), 10.1% showed radiologic progression (growth ≥3 mm, more aggressive Zabramski type, or hemorrhage), but acute hemorrhage was only 1.2%; 88.2% of progression events occurred within 2 years.

Imaging correlates of SH Symptomatic hemorrhage (SH) was associated with lesion growth, moderate-to-severe T1-hyperintensity, and edema at follow-up; baseline lesion size and location did not predict hemorrhage.

Symptom predictors New or worsening FND predicted hemorrhage, while seizure or headache alone did not; in multivariate analysis, only new/worsening FND remained independently associated with hemorrhage (OR 13.73, p<0.001).

Clinical implication Follow-up MRI is most justified when there is new or worsening FND; routine surveillance in asymptomatic patients has limited diagnostic yield but may be reasonable in select situations.

Special cases MRI may still be considered for atypical, prolonged headaches distinct from baseline and not responsive to over-the-counter medication, or for changing/new seizure patterns based on clinical judgment.

Posted on

Efficacy of Vancomycin Powder Prophylaxis in 987 Cranial Surgeries for Nonmalignant Pathology

Neurosurgery 98:1076–1084, 2026

This study evaluates whether prophylactic subgaleal vancomycin powder reduces surgical site infections (SSIs) after 987 craniotomies for nonmalignant pathology. In a retrospective cohort (682 with vancomycin, 305 without), overall SSI incidence was very low and did not differ significantly between groups, with six infections recorded and diverse cultured pathogens.

The authors contrast prior studies biased toward malignant, high-risk populations, discuss potential harms of indiscriminate vancomycin use (resistance, wound complications), and recommend a more selective, evidence-based application while calling for larger multicenter research to define high-risk subgroups and dosing effects.

Objective Assess whether prophylactic subgaleal vancomycin powder reduces surgical site infections (SSI) in nonmalignant cranial surgeries.

Design Retrospective chart review of 987 nonmalignant cranial surgeries (July 2021–June 2024), comparing vancomycin powder (n=682) vs no vancomycin powder (n=305).

Intervention Vancomycin cohort received 1 g powder applied over the bone flap before galeal closure; all patients received standard IV cefazolin, chlorhexidine prep, and postoperative incisional bacitracin.

Primary outcome SSI incidence was not significantly different: 0.3% without vancomycin vs 0.7% with vancomycin (P = .578), with 6 total infections.

SSI distribution Infections occurred mainly with atypical meningiomas (3/6) and schwannomas (2/6), plus 1 amoebic abscess case.

Pathogens 7 pathogens were cultured from 6 SSI cases; Cutibacterium acnes was most common (3/6), and Klebsiella aerogenes occurred in 2 vancomycin cases (vancomycin-resistant).

Interpretation Routine prophylactic vancomycin powder in nonmalignant cranial surgery may be unnecessary given the very low SSI rate and lack of demonstrated benefit.

Caveats Retrospective design with potential selection bias and only 6 SSI events; larger/multicenter studies are needed to identify any high-risk subgroups who might benefit.

Posted on

The Timing of Diskectomy as a Predictor of Outcomes in Patients With Lumbar Disk Herniation

Neurosurgery 98:1051–1062, 2026

This prospective cohort study evaluates how the duration of preoperative symptoms influences outcomes after microdiskectomy for lumbar disk herniation. Outcomes measured include radicular pain, low back pain, disability (ODI), and motor and sensory deficits, with follow-up at 6 weeks, 6, 12, and 24 months in 1,120 analyzed patients.

Key finding: surgical intervention within one month of symptom onset yields faster, more pronounced pain relief and neurological recovery, whereas symptoms persisting beyond two years associate with the highest rates of residual motor and sensory deficits at 24 months.

Objective Evaluate how the preoperative duration of low back pain, disability, radicular leg pain, and motor/sensory deficits relates to postoperative outcomes after microdiskectomy for lumbar disk herniation (LDH).

Design/setting Prospective cohort (April 2015–October 2022) of adults undergoing microdiskectomy for symptomatic LDH with imaging-confirmed herniation consistent with symptoms.

Assessments & follow-up Pain measured by NRS, disability by ODI, motor deficit by MRC grading, sensory deficit as present/absent; assessed pre-op and at 6 weeks, 6, 12, and 24 months post-op.

Cohort size 1222 patients enrolled; 69 recurrences and 33 lost to follow-up excluded, leaving 1120 for statistical analyses.

Symptom-duration grouping Patients categorized by symptom duration thresholds ≤1, ≤6, ≤24, and ≥25 months for LDH-related symptoms (pain/disability/neurologic symptomatology).

Key outcome (timing) Surgery performed within 1 month of symptom onset was associated with more favorable outcomes than longer symptom duration, including faster improvement in neurological deficit and more significant radicular pain relief.

Residual deficits at 2 years Residual motor and sensory deficits at 24 months were least common when preoperative neurological symptoms lasted ≤1 month, and more common when symptoms exceeded 1 month.

Worst outcomes with long duration LDH symptoms persisting beyond 2 years were associated with the least favorable postoperative outcomes, including the highest residual motor and sensory deficits at 2 years.

Posted on

Awake Versus Asleep Craniotomy for Glioma: A Comparison of Survival and Costs Using Time-Driven Activity-Based Costing

Operative Neurosurgery 30:653–667, 2026

Awake versus asleep (general anesthesia) craniotomy are two approaches for glioma resection, and this work compares their intraoperative costs and survival outcomes.

Key Insights and Themes

Clinical question centers on whether awake craniotomy (AC) differs from asleep craniotomy under general anesthesia (GA) in intraoperative cost and in survival for glioma patients.

Cohort identification included all glioma resections at one institution from 2017–2022: 298 GA cases and 67 AC cases.

Awake-craniotomy indication primarily involved tumors in eloquent brain regions to allow intraoperative monitoring of neural function, while noneloquent tumors typically started under GA.

Costing method (TDABC) used process maps plus automated time-stamped extraction from the electronic medical record to capture intraoperative resources and time.

Cost components were dominated by supplies and personnel, with other elements (turnover and overhead) described as relatively minor contributors.

Baseline overall intraoperative cost had a median total of $6600 (IQR $2875), largely driven by supply cost (median $3178) and personnel cost (median $3141).

Operating-room time was longer for AC (median 5.2 hours) than GA (median 4.5 hours), and AC had about 30 additional minutes of incision-to-closure time.

Patient/tumor comparability showed GA patients were older, but there were no differences in WHO grade distribution or extent of resection between groups.

Unadjusted total cost difference showed higher median intraoperative cost for AC ($8506) versus GA ($6033).

Unadjusted subcomponent differences showed AC had higher median supply cost ($4238 vs $2928) and higher median personnel cost ($4111 vs $2962) than GA.

Adjusted total cost effect found AC associated with $2175 additional intraoperative cost versus GA after accounting for confounders.

Adjusted cost drivers attributed the added AC cost to higher supply cost (+$1272) and higher personnel cost (+$970).

Supply subcomponents were higher for AC than GA across consumables, implants, sterilization, and medications in unadjusted comparisons.

Personnel mix differed in that neurology attendings/fellows were included in AC but not GA at this institution, contributing to personnel-cost differences.

Unadjusted survival showed higher overall survival for AC on Kaplan–Meier analysis (log-rank P = .011), while progression-free survival did not significantly differ (log-rank P = .106).

Adjusted survival showed no significant differences between AC and GA in overall survival (HR 0.84, P = .48) or progression-free survival (HR 0.9, P = .66) after multivariable adjustment.

Key limitation (missing GA neuromonitoring costs) is that electrophysiological neuromonitoring personnel costs for GA were not captured due to EMR documentation limits.

Scope limitation (episode-of-care costs) is that the analysis focuses on intraoperative costs, and commenters note postoperative/inpatient costs could change conclusions about overall expense.

Conclusion

Awake craniotomy for glioma resection had higher intraoperative costs than asleep craniotomy, but after adjustment it showed no significant survival advantage in overall or progression-free survival.

Posted on

Long-Term Clinical Benefits of Age-Adjusted Sagittal Correction in Adult Spinal Deformity Surgery

Neurosurgery 98:1040–1050, 2026

This study evaluates long-term clinical outcomes of age-adjusted sagittal alignment correction in adult spinal deformity (ASD) surgery by integrating PI–LL, pelvic tilt, T1 pelvic angle, and SVA. Using hierarchical cluster analysis on 386 patients with long-segment fusion, three postoperative alignment patterns emerged—undercorrected, matched, and overcorrected—correlated with differing radiographic trajectories and complication rates.

Patients in the matched-correction cluster achieved the best balance of clinical improvement (ODI and SRS-22r) and minimized proximal junctional kyphosis/failure, while overcorrection increased mechanical complications despite stronger radiographic correction. The results support a multi-parameter, age-adjusted strategy and propose cluster-derived offset ranges as practical surgical benchmarks.

Aim Evaluate long-term benefits of age-adjusted sagittal alignment in adult spinal deformity surgery by integrating PI–LL, PT, TPA, and SVA using hierarchical cluster analysis.

Cohort Retrospective review of 386 ASD patients undergoing ≥5-level fusion including sacrum/pelvis, with minimum 2-year follow-up (mean follow-up 36.6 months).

Targeting method Postoperative offsets (target − current) for PI–LL, PT, TPA, and SVA were computed using published age-adjusted formulas from 6-week radiographs (or immediate postop if early PJK).

Clustering outcome Patients stratified into 3 clusters (A: 72, B: 211, C: 103) with cluster A undercorrected, cluster B balanced/matched, and cluster C overcorrected trends across all parameters.

Mechanical complications PJK/PJF rates differed by cluster, highest in cluster C (37.9%) vs cluster B (27.5%) and cluster A (20.9%) (P = .046).

Patient-reported outcomes At final follow-up, cluster B had significantly better ODI and SRS-22r outcomes than clusters A and C.

Parameter relationships Offsets showed strong correlations: PI–LL with PT (r = 0.77) and PI–LL with TPA (r = 0.79); weaker with SVA (r = 0.43).

Practical implication A balanced multi-parameter alignment profile (cluster B) best optimized outcomes while reducing complications, supporting integrating multiple sagittal targets rather than relying on a single parameter.

Posted on

Long-term outcomes of microvascular decompression for trigeminal neuralgia in multiple sclerosis

J Neurosurg 144:1122–1133, 2026

This systematic review and meta-analysis evaluates microvascular decompression (MVD) outcomes for trigeminal neuralgia in patients with multiple sclerosis (TN-MS). The authors pooled 30 studies (265 unique TN-MS patients), finding neurovascular compression in 96.6% and a pooled long-term pain-free (BNI I) success rate of about 30%, with low heterogeneity and primarily transient sensory complications.

The report discusses limited, mostly retrospective evidence, methodological limitations, and potential dual mechanisms of TN in MS. Authors conclude MVD yields lower success than in classic TN but remains a reasonable option for selected TN-MS patients with demonstrable neurovascular compression; they call for prospective studies and refined patient selection.

Objective Evaluate long-term pain relief and complications of microvascular decompression (MVD) for trigeminal neuralgia in patients with multiple sclerosis (TN-MS), a group traditionally considered poor candidates for MVD.

Methods Systematic review/meta-analysis (PRISMA) of PubMed, Embase, Scopus, and Web of Science (search June 2024); primary endpoint was long-term pain-free status BNI I at final follow-up using random-effects meta-analysis of proportions.

Evidence base 30 studies were included, covering 429 TN-MS patients treated with MVD, representing 265 unique patients.

Neurovascular compression Compression was identified in 96.6% of reported TN-MS cases (via MRI and/or intraoperative findings).

Long-term efficacy Pooled long-term pain-free outcome (BNI I) after MVD was 30.2% (95% CI 24.2%–36.9%), with low heterogeneity across analyses.

Complications The most commonly reported complication after MVD was transient facial numbness (with other complications variably reported).

Interpretation MVD is less effective in TN-MS than in classic TN, but can still provide meaningful benefit, particularly when neurovascular compression is present.

Conclusion/implication MVD should not be categorically excluded for TN-MS; further prospective studies are needed to improve selection and outcomes.

Posted on

The Fast and the Fragile: Neurosurgical Trauma in the Age of Micromobility

Neurosurgery 98:974–983, 2026

This study analyzes five years of micromobility-related trauma at a Level-1 urban trauma center, quantifying injury mechanisms, patient demographics, device types, and neurosurgical outcomes. Findings show rising electric device involvement, frequent motor-vehicle collisions, low helmet use, substantial ICU and operative resource needs, and a 1.2% in-hospital mortality.

Key implications highlight pedestrians—especially those struck by electric devices—as highest-risk, evening hours and alcohol as modifiable contributors, and helmet use and infrastructure redesign as actionable prevention targets to reduce neurosurgical burden.

Scope Retrospective cohort review of micromobility-related injuries (electric/mechanical bikes and scooters, plus pedestrians struck) presenting to Bellevue Hospital Center (Level-1 trauma center) from 2018–2023, assessing mechanisms, risk factors, injury patterns, and outcomes.

Growing burden 914 patients accounted for 6.9% of all trauma admissions; annual volume and electric-device involvement increased over time.

Mechanisms The most common injury mechanism was collision with a motor vehicle (49.9%), followed by falls (33.8%).

Clinical severity & utilization Most patients required hospital admission (~68%), 30.2% required ICU care, median LOS was 3 days, about half underwent a procedure/intervention, and in-hospital mortality was 1.2%.

Neurotrauma patterns TBI was frequent (about one-third of patients) and neurosurgical interventions occurred in 3.7% (eg, craniotomy/hemicraniectomy 1.1%, ICP monitor/EVD 0.8%, spine decompression/instrumentation 0.7%).

Helmet use Helmet use was low (31.7% with documented status); not wearing a helmet was associated with higher rates of TBI and craniofacial trauma.

Alcohol & timing Alcohol intoxication was common and associated with lower helmet use and higher TBI/craniofacial injury; injuries clustered in evening/overnight hours, indicating modifiable environmental/behavioral risks.

Highest-risk group Pedestrians had the most severe outcomes (higher TBI, admission and ICU rates), with greater injury severity when struck by electric devices; after propensity matching, electric vs mechanical riders had no significant outcome differences.

Proudly powered by WordPress